Freshfields Bruckhaus Deringer LLP has advised Bioeq IP AG on its license and development agreement with Coherus BioSciences, Inc.
The agreement enables Coherus to exclusively market and distribute Bioeq’s biosimilar candidate to Lucentis® (ranibizumab) in the United States. The launch of the product is planned in 2021.
According to the license and development agreement, Bioeq will receive upfront and launch milestone payments and the parties will share the profits achieved with sales of the product in the U.S.
Bioeq is a Swiss biopharmaceutical company active in the development, licensing and commercialization of biosimilars. Bioeq is a joint venture between the Polpharma Biologics Group and the Strüngmann Group.
Coherus is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets.
The Freshfields team comprised partner Jochen Dieselhorst (Picture) and associate Philipp Lehmann.
Law Firms: Freshfields Bruckhaus Deringer LLP;
Clients: Bioeq IP AG;